Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I’m personally not expecting Avacta to comment on the issues that have faced the UK diagnostics industry getting approved by DHSC.
Avacta and Medusa19 focussed away from the UK months ago. They have of course kept their “hat in the ring” just in case the Uk see sense, but don’t underestimate Richard Hughes ability to pull off some unbelievable deals in the weeks ahead.
He is known as one of the best deal makers out there for a reason.
Avacta already RNS’d the deal with point and royalty structure.
This looks like a strategic move by both Point and Avacta to land some big deals in this area.
Point are clearly hugely excited about the Canseek technology……
https://twitter.com/lee_williams97/status/1473732965003845651?s=21
Matt Vincent will be pushing Canseek right throughout Asia, which only benefits Avacta further….
“Under the terms of the agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT”
There could be some serious sublicensing income to come from this partnership.
This is very good news indeed.
https://twitter.com/lee_williams97/status/1464649533133107204?s=21
See my post from a few weeks ago.
https://twitter.com/sirrogergale/status/1476156163079163906?s=21
“I have spoken to Secretary of State, there is a world shortage of Lateral Flow & PCR test supplies, but we are buying all that’s available. Best advice to constituents- keep trying online, as stock are being released hourly”
Definitely legs in this imo.
Just take a look at LSAI biggest shareholders, all Boohoo/M19 folks.
https://www.locationsciencesgroup.ai/investor-relations/significant-shareholders/
They have over 20 million of losses sat on the books which would be very attractive for a M19 and an RTO.
Merry Xmas and best wishes to all my fellow shareholders and the amazing team at Avacta.
Avacta will blow the bloody doors off in 2022, that I have absolutely no doubt in. January looks very very interesting;)
Have a good one everybody!
https://www.linkedin.com/posts/medusa19_meduflow-medusa19-avacta-activity-6879788242233765888-UVlZ
Medusa19 have successfully received the CE mark from a European Notified Body for the MeduFlow® test.
MeduFlow® by Medusa19 is the first British designed and manufactured test to obtain a home use CE mark. MeduFlow® is a lateral flow test (LFT) using a simple and comfortable anterior nasal swab to qualitatively detect the SARS-CoV-2 antigen. The product provides results on the spot in 20 minutes.
The MeduFlow® SARS-CoV-2 antigen lateral flow test has been developed using Avacta's proprietary Affimer® platform to identify individuals with a higher viral load of the SARS-CoV-2 virus who are therefore more likely to infect others.
Those options this week were exercised at 85.5p.
That’s confidence spending over 108k, we’re due to expire until 2025 too.
https://avacta.com/wp-content/uploads/2021/05/Avacta-ARA-2020.pdf
Page 105 of annual report.